Jornada Comités ética

#ÉticaInvestigaciónSSPAOrganiza: Secretaría General de Salud Pública e I+D+I en Salud. Consejería de Salud y Consumo. Comité Coordinador de Ética de la Investigación Biomédica de Andalucía, con la colaboración de Escuela Andaluza de Salud Pública. Fecha: 6 y 7 de junio de 2024. Lugar de celebración: Escuela Andaluza de Salud Pública. Coordinación científica – Mariano Aguayo…

Jornada Cáncer cabeza y cuello

#CáncerCabeza-CuelloJornada PRESENCIAL Y VIRTUAL Derivación temprana y Detección Precoz del Cáncer de Cabeza y Cuello en Andalucía   Coordinación Científica Dr. Antonio Rueda Domínguez. Jefe de Servicio de Oncología Médica. Hospital Regional Universitario de Málaga. Dra. Maria José Sánchez Pérez. Profesora de la Escuela Andaluza de Salud Pública. Directora del Registro de Cáncer de Granada.…

Long-term survival for lymphoid neoplasms and national health expenditure (EUROCARE-6): a retrospective, population-based study

Background Management of lymphoid malignancies requires substantial health system resources. Total national health expenditure might influence population-based lymphoid malignancy survival. We studied the long-term survival of patients with 12 lymphoid malignancy types and examined whether different levels of national health expenditure might explain differences in lymphoid malignancy prognosis between European countries and regions. Methods For…

Tiered Pricing and Alternative Mechanisms for Equitative Access to Vaccines in Latin America: A Narrative Review of the Literature

Methods We conducted a narrative review to explore and describe alternatives for equitable vaccine access in Latin America. We searched and considered the main access strategies reported in the literature through PubMed, Science Direct, and Google Scholar. Additionally, we reviewed the web sites of key stakeholders. The search was conducted using the following keywords: (“access”…

Economic assessment of abemaciclib for the adjuvant treatment of luminal HER2- breast cancer from the perspective of the Spanish health system

Introduction Abemaciclib is an oral inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6). Data from the clinical trial monarchE (2023) showed improved survival from invasive disease. The aim of the present article was to conduct an economic assessment of adjuvant treatment with abemaciclib in women with luminal, HER2- and node-positive breast cancer. Methods A Markov…